FENC

Company Overview — What Does FENNEC PHARMACEUTICALS INC. Do?

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. FENNEC PHARMACEUTICALS INC. (FENC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Rostislav C. Raykov and employs approximately 10 people. With a market capitalization of $221M, FENC is one of the notable companies in the Healthcare sector.

FENNEC PHARMACEUTICALS INC. (FENC) Stock Rating — Avoid (April 2026)

As of April 2026, FENNEC PHARMACEUTICALS INC. receives a Avoid rating with a composite score of 33.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.FENC ranks #3,924 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, FENNEC PHARMACEUTICALS INC. ranks #671 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

FENC Stock Price and 52-Week Range

FENNEC PHARMACEUTICALS INC. (FENC) currently trades at $6.00. The stock lost $0.40 (6.3%) in the most recent trading session. The 52-week high for FENC is $9.92, which means the stock is currently trading -39.5% from its annual peak. The 52-week low is $4.68, putting the stock 28.2% above its annual trough. Recent trading volume was 323K shares, suggesting relatively thin trading activity.

Is FENC Overvalued or Undervalued? — Valuation Analysis

FENNEC PHARMACEUTICALS INC. (FENC) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.14x, versus the sector average of 2.75x. The price-to-sales ratio is 5.76x, compared to 1.66x for the average Healthcare stock.

At current multiples, FENNEC PHARMACEUTICALS INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

FENNEC PHARMACEUTICALS INC. Profitability — ROE, Margins, and Quality Score

FENNEC PHARMACEUTICALS INC. (FENC) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -30.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -15.2% versus the sector average of -33.1%.

On a margin basis, FENNEC PHARMACEUTICALS INC. reports gross margins of 95.7%, compared to 71.5% for the sector. The operating margin is -28.4% (sector: -66.1%). Net profit margin stands at -33.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 71.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

FENC Debt, Balance Sheet, and Financial Health

FENNEC PHARMACEUTICALS INC. has a debt-to-equity ratio of 99.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 6.37x, indicating strong short-term liquidity. Total debt on the balance sheet is $19M. Cash and equivalents stand at $22M.

FENC has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for FENNEC PHARMACEUTICALS INC. is 43/100, reflecting average volatility within the normal range for its sector.

FENNEC PHARMACEUTICALS INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, FENNEC PHARMACEUTICALS INC. reported revenue of $38M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-11M. Gross margin was 95.7%. Operating income came in at $-9M.

In FY 2025, FENNEC PHARMACEUTICALS INC. reported revenue of $45M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-10M. Revenue grew -6.1% year-over-year compared to FY 2024. Operating income came in at $-6M.

In Q3 2025, FENNEC PHARMACEUTICALS INC. reported revenue of $12M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-638,000. Revenue grew 78.7% year-over-year compared to Q3 2024. Operating income came in at $-189,000.

In Q2 2025, FENNEC PHARMACEUTICALS INC. reported revenue of $10M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-3M. Revenue grew 32.9% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, FENNEC PHARMACEUTICALS INC. has demonstrated a growth trajectory, with revenue expanding from $7M to $38M. Investors analyzing FENC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

FENC Dividend Yield and Income Analysis

FENNEC PHARMACEUTICALS INC. (FENC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

FENC Momentum and Technical Analysis Profile

FENNEC PHARMACEUTICALS INC. (FENC) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

FENC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, FENNEC PHARMACEUTICALS INC. (FENC) ranks #671 out of 838 stocks based on the Blank Capital composite score. This places FENC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing FENC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full FENC vs S&P 500 (SPY) comparison to assess how FENNEC PHARMACEUTICALS INC. stacks up against the broader market across all factor dimensions.

FENC Next Earnings Date

No upcoming earnings date has been announced for FENNEC PHARMACEUTICALS INC. (FENC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy FENC? — Investment Thesis Summary

The quantitative profile for FENNEC PHARMACEUTICALS INC. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 30/100 indicates premium valuation.

In summary, FENNEC PHARMACEUTICALS INC. (FENC) earns a Avoid rating with a composite score of 33.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on FENC stock.

Related Resources for FENC Investors

Explore more research and tools: FENC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare FENC head-to-head with peers: FENC vs AZN, FENC vs SLGL, FENC vs VMD.